CDC42 and prostate carcinoma: Similarly, in the targeted treatment of prostate cancer with nintedanib (61), prostate cancer cells acquired resistance to nintedanib and survived by activating entosis formed by the upregulation of E-cadherin and ROCK1/2 through the PI3K/CDC42 signaling pathway.